Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Database
Language
Publication year range
1.
ACS Infect Dis ; 9(7): 1387-1395, 2023 07 14.
Article in English | MEDLINE | ID: mdl-37310810

ABSTRACT

Malaria, a mosquito-borne disease caused by several parasites of the Plasmodium genus, remains a huge threat to global public health. There are an estimated 0.5 million malaria deaths each year, mostly among African children. Unlike humans, Plasmodium parasites and a number of important pathogenic bacteria employ the methyl erythritol phosphate (MEP) pathway for isoprenoid synthesis. Thus, the MEP pathway represents a promising set of drug targets for antimalarial and antibacterial compounds. Here, we present new unsaturated MEPicide inhibitors of 1-deoxy-d-xylulose-5-phosphate reductoisomerase (DXR), the second enzyme of the MEP pathway. A number of these compounds have demonstrated robust inhibition of Plasmodium falciparum DXR, potent antiparasitic activity, and low cytotoxicity against HepG2 cells. Parasites treated with active compounds are rescued by isopentenyl pyrophosphate, the product of the MEP pathway. With higher levels of DXR substrate, parasites acquire resistance to active compounds. These results further confirm the on-target inhibition of DXR in parasites by the inhibitors. Stability in mouse liver microsomes is high for the phosphonate salts, but remains a challenge for the prodrugs. Taken together, the potent activity and on-target mechanism of action of this series further validate DXR as an antimalarial drug target and the α,ß-unsaturation moiety as an important structural component.


Subject(s)
Antimalarials , Fosfomycin , Child , Humans , Animals , Mice , Plasmodium falciparum , Fosfomycin/pharmacology , Fosfomycin/chemistry , Pentosephosphates/metabolism , Antimalarials/pharmacology , Antimalarials/chemistry
2.
Metabolites ; 13(3)2023 Feb 28.
Article in English | MEDLINE | ID: mdl-36984798

ABSTRACT

Over 33% of Americans are labeled as obese, leading the World Health Organization to designate obesity as a major public health problem. One consequence of obesity is the development of metabolic syndrome, a condition which has been correlated to an increased risk for developing cardiovascular disease and Type 2 diabetes. Prolonged ingestion of a higher-fat diet, one cause of obesity, results in alterations to the gut microbiome. These alterations are implicated to have a profound role in the evolution and progression of obesity-linked diseases. Probiotics are associated with positive health effects such as limiting pathogen colonization, aiding in digestion, and vitamin synthesis. Using Ossabaw pigs as a model for obesity, and in conjunction with our previous research, we performed an in-depth, nontargeted, metabolomic analysis on select organs to elucidate the effects of dietary supplementation with the probiotic Lacticaseibacillus paracasei. We focused our analysis on the effects of probiotic supplementation on a higher-fat (obesogenic) diet and a nutritionally balanced diet. Notably, our findings reveal that the brain cortex is highly sensitive to dietary influencers, and with probiotic supplementation, several aberrant metabolites associated with a higher-fat diet revert to healthy levels, thus demonstrating the potential for a probiotic intervention for obesity-linked disease.

3.
Sci Rep ; 10(1): 11746, 2020 07 16.
Article in English | MEDLINE | ID: mdl-32678173

ABSTRACT

Category A and B biothreat agents are deemed to be of great concern by the US Centers for Disease Control and Prevention (CDC) and include the bacteria Francisella tularensis, Yersinia pestis, Burkholderia mallei, and Brucella species. Underscored by the impact of the 2020 SARS-CoV-2 outbreak, 2016 Zika pandemic, 2014 Ebola outbreak, 2001 anthrax letter attacks, and 1984 Rajneeshee Salmonella attacks, the threat of future epidemics/pandemics and/or terrorist/criminal use of pathogenic organisms warrants continued exploration and development of both classic and alternative methods of detecting biothreat agents. Volatile organic compounds (VOCs) comprise a large and highly diverse group of carbon-based molecules, generally related by their volatility at ambient temperature. Recently, the diagnostic potential of VOCs has been realized, as correlations between the microbial VOC metabolome and specific bacterial pathogens have been identified. Herein, we describe the use of microbial VOC profiles as fingerprints for the identification of biothreat-relevant microbes, and for differentiating between a kanamycin susceptible and resistant strain. Additionally, we demonstrate microbial VOC profiling using a rapid-throughput VOC metabolomics method we refer to as 'simultaneous multifiber headspace solid-phase microextraction' (simulti-hSPME). Finally, through VOC analysis, we illustrate a rapid non-invasive approach to the diagnosis of BALB/c mice infected with either F. tularensis SCHU S4 or Y. pestis CO92.


Subject(s)
Metabolomics/methods , Tularemia/metabolism , Volatile Organic Compounds/metabolism , Animals , Betacoronavirus/isolation & purification , COVID-19 , Coronavirus Infections/epidemiology , Coronavirus Infections/metabolism , Coronavirus Infections/virology , Disease Outbreaks , Drug Resistance, Microbial/drug effects , Drug Resistance, Microbial/genetics , Female , Francisella tularensis/drug effects , Francisella tularensis/isolation & purification , Francisella tularensis/metabolism , Kanamycin/pharmacology , Mice , Mice, Inbred BALB C , Pandemics , Pneumonia, Viral/epidemiology , Pneumonia, Viral/metabolism , Pneumonia, Viral/virology , SARS-CoV-2 , Solid Phase Microextraction , Tularemia/microbiology , Tularemia/pathology , Tularemia/veterinary , Volatile Organic Compounds/analysis , Volatile Organic Compounds/isolation & purification , Yersinia pestis/drug effects , Yersinia pestis/isolation & purification , Yersinia pestis/metabolism
4.
Anal Biochem ; 542: 63-75, 2018 02 01.
Article in English | MEDLINE | ID: mdl-29180070

ABSTRACT

The rise of antibacterial resistance among human pathogens represents a problem that could change the landscape of healthcare unless new antibiotics are developed. The methyl erythritol phosphate (MEP) pathway represents an attractive series of targets for novel antibiotic design, considering each enzyme of the pathway is both essential and has no human homologs. Here we describe a pilot scale high-throughput screening (HTS) campaign against the first and second committed steps in the pathway, catalyzed by DXP reductoisomerase (IspC) and MEP cytidylyltransferase (IspD), using compounds present in the commercially available LOPAC1280 library as well as in an in-house natural product extract library. Hit compounds were characterized to deduce their mechanism of inhibition; most function through aggregation. The HTS workflow outlined here is useful for quickly screening a chemical library, while effectively identifying false positive compounds associated with assay constraints and aggregation.


Subject(s)
Aldose-Ketose Isomerases/antagonists & inhibitors , Anti-Bacterial Agents/analysis , Enzyme Inhibitors/analysis , High-Throughput Screening Assays , Nucleotidyltransferases/antagonists & inhibitors , Aldose-Ketose Isomerases/metabolism , Anti-Bacterial Agents/pharmacology , Enzyme Inhibitors/pharmacology , Molecular Structure , Mycobacterium tuberculosis/drug effects , Mycobacterium tuberculosis/enzymology , Nucleotidyltransferases/metabolism , Recombinant Proteins/metabolism , Yersinia pestis/drug effects , Yersinia pestis/enzymology
5.
Methods Mol Biol ; 1606: 333-340, 2017.
Article in English | MEDLINE | ID: mdl-28502010

ABSTRACT

The field of metabolomics is greatly being refined by the addition of new technologies. LC-MS has allowed researchers to explore additional metabolites which were not originally captured through GC-MS. Through the customizability of the LC columns and mass spectrometer, it is now easier to tailor the instrument to your research needs. Herein, we describe a protocol for sample preparation and data acquisition for a global metabolomic analysis of tissues or feces.


Subject(s)
Chromatography, Liquid/methods , Mass Spectrometry/methods , Metabolomics/methods , Feces/chemistry , Humans , Specimen Handling/methods , Tissue Distribution
6.
Methods Mol Biol ; 1606: 341-352, 2017.
Article in English | MEDLINE | ID: mdl-28502011

ABSTRACT

Metabolomics allows for the investigation of the small molecules found within living systems. Based on the design of the experiments, it is not uncommon for these analyses to include matrices of thousands of variables. In order to handle such large datasets, many have turned to multivariate statistical analyses to analyze and understand their data. Herein, we present protocols for using R to analyze metabolomic data using some of the more common multivariate statistical techniques.


Subject(s)
Computational Biology/methods , Metabolomics/methods , Animals , Humans , Multivariate Analysis , Principal Component Analysis
7.
PLoS One ; 10(3): e0119362, 2015.
Article in English | MEDLINE | ID: mdl-25751150

ABSTRACT

Studies have shown that excessive alcohol consumption impacts the intestinal microbiota composition, causing disruption of homeostasis (dysbiosis). However, this observed change is not indicative of the dysbiotic intestinal microbiota function that could result in the production of injurious and toxic products. Thus, knowledge of the effects of alcohol on the intestinal microbiota function and their metabolites is warranted, in order to better understand the role of the intestinal microbiota in alcohol associated organ failure. Here, we report the results of a differential metabolomic analysis comparing volatile organic compounds (VOC) detected in the stool of alcoholics and non-alcoholic healthy controls. We performed the analysis with fecal samples collected after passage as well as with samples collected directly from the sigmoid lumen. Regardless of the approach to fecal collection, we found a stool VOC metabolomic signature in alcoholics that is different from healthy controls. The most notable metabolite alterations in the alcoholic samples include: (1) an elevation in the oxidative stress biomarker tetradecane; (2) a decrease in five fatty alcohols with anti-oxidant property; (3) a decrease in the short chain fatty acids propionate and isobutyrate, important in maintaining intestinal epithelial cell health and barrier integrity; (4) a decrease in alcohol consumption natural suppressant caryophyllene; (5) a decrease in natural product and hepatic steatosis attenuator camphene; and (6) decreased dimethyl disulfide and dimethyl trisulfide, microbial products of decomposition. Our results showed that intestinal microbiota function is altered in alcoholics which might promote alcohol associated pathologies.


Subject(s)
Ethanol/adverse effects , Feces/chemistry , Metabolome/drug effects , Microbiota/drug effects , Volatile Organic Compounds/metabolism , Adult , Alkanes/metabolism , Bicyclic Monoterpenes , Case-Control Studies , Disulfides/metabolism , Fatty Acids, Volatile/metabolism , Fatty Alcohols/metabolism , Feces/microbiology , Female , Humans , Male , Middle Aged , Polycyclic Sesquiterpenes , Sesquiterpenes/metabolism , Sulfides/metabolism , Terpenes/metabolism , Young Adult
8.
J Ind Microbiol Biotechnol ; 38(5): 607-15, 2011 May.
Article in English | MEDLINE | ID: mdl-20714781

ABSTRACT

Cyathin A(3), produced by the fungus Cyathus helenae, is a member of the cyathane family of diterpene natural products. While many of the cyathanes display antibacterial/antimicrobial activity or have cytotoxic activity against human cancer cell lines, their most exciting therapeutic potential is derived from their ability to induce nerve growth factor (NGF) release from glial cells, making the cyathanes attractive lead molecules for the development of neuroprotective therapeutics to prevent/treat Alzheimer's disease. To investigate if cyathin A(3) has NGF-inducing activity, we set out to obtain it using published C. helenae bench-scale fungal fermentations. However, to overcome nonproducing fermentations, we developed an alternative, bacteria-induced static batch fermentation approach to the production of cyathin A(3), as described in this report. HPLC, UV absorption spectra, and mass spectrometry identify cyathin A(3) in fungal fermentations induced by the timely addition of Escherichia coli K12 or Bacillus megabacterium. Pre-filtration of the bacterial culture abolishes cyathin A(3) induction, suggesting that bacteria-associated media changes or physical interaction between the fungus and bacteria underlie the induction mechanism. Through alteration of incubation conditions, including agitation, the timing of induction, and media composition, we optimized the fermentation to yield nearly 1 mg cyathin A(3)/ml media, a sixfold increase over previously described yields. Additionally, by comparison of fermentation profiles, we reveal that cyathin A(3) biosynthesis is regulated by carbon catabolite repression. We have used an enzyme-linked immunosorbent assay to illustrate that cyathin A(3) induces NGF release from cultured glial cells, and therefore cyathin A(3) warrants further examination in the development of neuroprotective therapeutics.


Subject(s)
Cyathus/metabolism , Diterpenes/pharmacology , Fermentation , Nerve Growth Factor/metabolism , Bacillus megaterium/physiology , Cell Line, Tumor , Diterpenes/chemistry , Diterpenes/metabolism , Enzyme-Linked Immunosorbent Assay , Escherichia coli K12/physiology , Humans , Microbial Interactions
SELECTION OF CITATIONS
SEARCH DETAIL
...